Fig. 1

miR-8072 suppresses TNBC tumor progression and predicts favorable prognosis. (A) Serum levels of miR-8072 in breast cancer, benign breast disease, and non-cancer samples were analyzed using data from GEO (GSE73002) (**P < 0.01). B The relationships between miR-8072 level and overall survival (OS) in breast cancer patients were analyzed using public database Kaplan–Meier plotter (https://kmplot.com/analysis/index.php?p=service&cancer=breast_mirna). 1062 breast cancer patients were included, 525 cases were in miR-8072 low-expression cohort, and 537 cases were in miR-8072 high-expression cohort. The median survival for the high-expression cohort of miR-8072 is 115.4 months, while it is 148.53 months for the low-expression cohort of miR-8072 (upper panel). 97 TNBC patients were included for analysis. Among them, 28 cases were in miR-8072 low-expression cohort, and 69 cases were in miR-8072 high-expression cohort. The upper quartile survival for cohorts with high-expression of miR-8072 is 98.83 months, while it is 36.43 months for cohorts with low-expression of miR-8072 (lower panel). C MDA-MB-231 cells with stably overexpressed miR-8072 or control (Ctrl) cells were subcutaneously implanted in nude mice, tumor volume were measured every 7 days. D Tumor nodules were collected and weighed 35 days later after implantation. E Expression of Ki67 in the tumor nodules was detected by immunohistochemistry